Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;108(12):3491-3495.
doi: 10.3324/haematol.2023.283154.

CD47 expression in acute myeloid leukemia varies according to genotype

Andrea Marra  1 , Ayse U Akarca  2 , Giovanni Martino  3 , Alan Ramsay  2 , Stefano Ascani  4 , Vincenzo Maria Perriello  5 , Jenny O'Nions  6 , Andrew J Wilson  6 , Rajeev Gupta  7 , Anna Childerhouse  2 , Ian Proctor  2 , Manuel Rodriguez-Justo  2 , Sabine Pomplun  2 , Maria Paola Martelli  5 , Cristina Lo Celso  8 , Brunangelo Falini  5 , Teresa Marafioti  9
Affiliations

CD47 expression in acute myeloid leukemia varies according to genotype

Andrea Marra et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Immunohistochemical expression of CD47 immune antigen across genomic subtypes of acute myeloid leukemia. (A and B) Strong positive (intensity score: 3) and diffuse expression of CD47 by leukemic cells in a patient with CBFβ/MYH11-rearranged acute myeloid leukemia (AML, original magnification 4X (A) and 40X (B)). (C and D) CD47-weak positive expression (intensity score: 1) by leukemic cells in a patient with KMT2A/MLLT3-rearranged AML. Focal strong staining (black arrows) is seen in background dysplastic megakaryocytes and scattered small cells with round regular nuclei probably of lymphoid origin (asterisk) (original magnification 40X). (E and F) CD47-negative expression (intensity score: 0) by leukemic cells (E and F) in a patient with KMT2A-rearranged AML. Scattered background positive small/medium-sized rounded cells, most likely of lymphoid origin, show membranous CD47 expression (F, black arrows) (original magnification 40X). Immunostaining for CD47 was performed using recombinant anti-CD47 antibody, EPR21794 clone, Abcam.
Figure 2.
Figure 2.
CD47 mRNA expression across genomic subtypes of acute myeloid leukemia. Transcriptomic data were retrieved from the “Beat-AML” project (http://www.vizome.org/). Bioinformatic and statistics analyses were performed on RNA-sequencing data from bone marrow (BM) samples. Fragments per kilobase of transcript per million mapped reads (FPKM) values for each gene/sample were calculated from RNA-sequencing raw counts, using rpkm function of “edgeR” (R package). According to European LeukemiaNet genetic-risk categories, 10 distinct genomic subgroups of acute myeloid (AML) were identified: the low-risk category includes RUNX1/RUNX1T1, CBF/MYH11 and NPM1mutFLT3wt genotypes; the intermediate-risk category includes NPM1mutFLT3-internal tandem duplication (ITD), NPM1wtFLT3-ITD and KMT2A/MLLT3 genotypes; the high-risk category includes AML cases with the following genotypes, as KMT2A-rearrangement (other than KMT2A/MLLT3), GATA2/MECOM, monosomy 7, and complex karyotype.
See this image and copyright information in PMC

References

    1. Maute R, Xu J, Weissman IL. CD47-SIRPα-targeted therapeutics: status and prospects. Immunooncol Technol. 2022;13:100070. - PMC - PubMed
    1. Jaiswal S, Jamieson CH, Pang WW, et al. . CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271-285. - PMC - PubMed
    1. Majeti R, Chao MP, Alizadeh AA, et al. . CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-299. - PMC - PubMed
    1. Sallman D, Asch A, Kambhampati S, et al. . AML-196: the first-inclass anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results. Clin Lymphoma Myeloma Leuk. 2021;21:S290
    1. Daver NG, Vyas P, Kambhampati S, et al. . Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results. J Clin Oncol. 2022;40(Suppl 16):S7020. - PMC - PubMed

Publication types